CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Immune Globulin codes

15 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.89M services · est. ▲ 6.9% YoY · 11,226 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.85M observed fee-for-service services

See the national market for J1569 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3.97M services · est. ▲ 12.6% YoY · 8,003 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.95M observed fee-for-service services

See the national market for J1568 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3.79M services · est. ▲ 32.4% YoY · 4,325 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.82M observed fee-for-service services

See the national market for J1561 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0485 Injection, belatacept, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 2.18M services · est. ▲ 29.5% YoY · 417 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.16M observed fee-for-service services

See the national market for J0485 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1459 Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.05M services · est. ▲ 77.0% YoY · 867 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 500,244 observed fee-for-service services

See the national market for J1459 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1556 Injection, immune globulin (bivigam), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 894,775 services · est. ▼ 28.9% YoY · 740 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 429,595 observed fee-for-service services

See the national market for J1556 → ranked groups · states · 12-yr trend

HCPCS · Treatment J9332 Injection, efgartigimod alfa-fcab, 2mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 603,486 services · est. ▲ 39.7% YoY · 47 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 283,000 observed fee-for-service services

See the national market for J9332 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1576 Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 401,388 services · est. ▲ 523.3% YoY · 378 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 214,290 observed fee-for-service services

See the national market for J1576 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1575 Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 343,047 services · est. ▲ 12.8% YoY · 65 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 171,101 observed fee-for-service services

See the national market for J1575 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1599 Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 136,266 services · est. ▲ 15.4% YoY · 242 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 70,413 observed fee-for-service services

See the national market for J1599 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1555 Injection, immune globulin (cuvitru), 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 31,293 services · est. · 12 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 16,170 observed fee-for-service services

See the national market for J1555 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1554 Injection, immune globulin (asceniv), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 25,138 services · est. · 24 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 12,538 observed fee-for-service services

See the national market for J1554 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1557 Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 14,903 services · est. ▲ 24.4% YoY · 29 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 8,480 observed fee-for-service services

See the national market for J1557 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1566 Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 11,520 services · est. ▲ 53.0% YoY · 54 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,746 observed fee-for-service services

See the national market for J1566 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1670 Injection, tetanus immune globulin, human, up to 250 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 356 services · est. ▲ 77.1% YoY · 159 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 162 observed fee-for-service services

See the national market for J1670 → ranked groups · states · 12-yr trend